Opendata, web and dolomites

NSFTA SIGNED

New Strategies For Therapeutic Antibodies – Synthetic bispecific antibodies & Antibody-Drug Conjugates with controlled drug loading. General methods for unexplored ADCs and personalised therapies.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "NSFTA" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITY COLLEGE LONDON 

Organization address
address: GOWER STREET
city: LONDON
postcode: WC1E 6BT
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 224˙933 €
 EC max contribution 224˙933 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2020
 Duration (year-month-day) from 2020-01-15   to  2022-01-14

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY COLLEGE LONDON UK (LONDON) coordinator 224˙933.00

Map

 Project objective

Antibody-Drug Conjugates (ADCs) are revolutionary next-generation therapeutics. The number of ADCs in the clinic is constantly growing with four of them having now reached the market. Despite this great promise, the complex structure of antibodies results in drawbacks for their reliable modification to construct ADCs, thus impairing the full potential of ADCs. One of the major reasons for clinical failure is that it is hard to control the drug to antibody ratio (DAR) to obtain homogeneous structures. Furthermore, current synthetic methods give access to ADCs with a DAR limited to values of 2, 4 and 8, thus lowering the variety of species being tested and possibilities to balance their toxicity. Hence, new synthetic methods giving access to homo- or hetero-functional ADCs with a high control of the DAR would be tremendous progress; being highly impactful to the ADC field and related patient outcomes. Here, we propose innovative methods to functionalise antibodies. Based on a well-established, patented disulfide bond re-bridging method, and orthogonal click ligations, we will finely control antibody modification. This will yield: 1) Mono-functional ADCs with highly controlled DAR, including odd DARs (DAR 1, DAR 3...). This is fundamental to determine the optimal ratio between drug loading and hydrophobicity to obtain the best therapeutic activity. 2) Hetero-functional ADCs with controlled amount and site of functionalisation with different payloads. This includes production of DAR 11, DAR 111…several combinations of payloads are possible, paving the way to promising multi-therapies. 3) Fully synthetic bi-specific antibodies. Our method provides an unprecedented way to obtain bi-specific antibodies in a controlled and adaptable fashion from native antibodies, i.e. without requiring bioengineering. The project addresses unmet needs in the therapeutic antibody field and could bring unprecedented outlooks to this booming sector.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NSFTA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NSFTA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More  

MingleIFT (2020)

Multi-color and single-molecule fluorescence imaging of intraflagellar transport in the phasmid chemosensory cilia of C. Elegans

Read More  

EPIC (2019)

Evolution of Planktonic Gastropod Calcification

Read More